Comparison of Dosimetric and Biologic Effective Dose Parameters for Prostate and Urethra Using 131Cs and 125I for Prostate Permanent Implant Brachytherapy

International Journal of Radiation Oncology Biology Physics

Volumn 72, Issue 1, 2008, Pages 247-254

  Sahgal, Arjun ^a,b   Jabbari, Siavash ^a   Chen, Josephine ^a   Pickett, Barbie ^a   Roach III, Mack ^a   Weinberg, Vivian ^c   Hsu, I Chow ^a   Pouliot, Jean ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

125I; 131Cs; Biologic effective dose; Cesium 131; Dosimetric comparisons; Iodine 125; Prostate brachytherapy

Indexed keywords

125I; 131CS; BIOLOGIC EFFECTIVE DOSE; CESIUM-131; DOSIMETRIC COMPARISONS; EFFECTIVE DOSE; EFFECTIVE DOSES; IODINE-125; PROSTATE BRACHYTHERAPY;

DOSIMETRY;

CESIUM 131; IODINE 125; RADIOISOTOPE; UNCLASSIFIED DRUG;

ARTICLE; BRACHYTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; COMPARATIVE STUDY; DOSIMETRY; HUMAN; MALE; PERMANENT IMPLANT BRACHYTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION HAZARD; RADIOACTIVITY; SIMULATION; TREATMENT PLANNING; URETHRA;

BRACHYTHERAPY; CESIUM RADIOISOTOPES; FEASIBILITY STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; PROSTATE; PROSTATIC NEOPLASMS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RELATIVE BIOLOGICAL EFFECTIVENESS; URETHRA;

EID: 49549085304     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.05.013     Document Type: Article

References (26)

1. Sahgal A., and Roach III M. Permanent prostate seed brachytherapy: A current perspective on the evolution of the technique and its application. Nat Clin Pract Urol 4 (2007) 658-670
2. Prestidge B.R., and Bice W.S. Clinical outcomes of a phase II, multi-institutional cesium-131 permanent prostate brachytherapy trial. Brachytherapy 6 (2007) 78
3. Moran B.J., and Braccioforte M.G. Cesium-131 prostate brachytherapy: An early experience. Brachytherapy 6 (2007) 80
4. Lessard E., Kwa S.L., Pickett B., et al. Class solution for inversely planned permanent prostate implants to mimic an experienced dosimetrist. Med Phys 33 (2006) 2773-2782
5. Stock R.G., Stone N.N., Cesaretti J.A., et al. Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys 64 (2006) 527-533
6. Dale R.G. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol 58 (1985) 515-528
7. Crook J.M., Potters L., Stock R.G., et al. Critical organ dosimetry in permanent seed prostate brachytherapy: Defining the organs at risk. Brachytherapy 4 (2005) 186-194
8. Armpilia C.I., Dale R.G., Coles I.P., et al. The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants. Int J Radiat Oncol Biol Phys 55 (2003) 378-385
9. 125I permanent seed implants over a wide range of seed number, activity, and designs. Int J Radiat Oncol Biol Phys 58 (2004) 1298-1308
10. 125I seeds in inverse-planned prostate implants?. Int J Radiat Oncol Biol Phys 55 (2003) 234-244
11. Waterman F.M., Yue N., Corn B.W., et al. Edema associated with I-125 or Pd-103 prostate brachytherapy and its impact on post-implant dosimetry: An analysis based on serial CT acquisition. Int J Radiat Oncol Biol Phys 41 (1998) 1069-1077
12. 131Cs (model CS-1) seeds. Med Phys 33 (2006) 968-975
13. Yue N., Heron D.E., Komanduri K., et al. Prescription dose in permanent (131)Cs seed prostate implants. Med Phys 32 (2005) 2496-2502
14. 131Cs source. Med Phys 34 (2007) 754-762
15. Stock R.G., Stone N.N., Lo Y.C., et al. Postimplant dosimetry for (125)I prostate implants: Definitions and factors affecting outcome. Int J Radiat Oncol Biol Phys 48 (2000) 899-906
16. Zelefsky M.J., Kuban D.A., Levy L.B., et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 67 (2007) 327-333
17. Brenner D.J., and Hall E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43 (1999) 1095-1101
18. Brenner D.J., Martinez A.A., Edmundson G.K., et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52 (2002) 6-13
19. Kal H.B., and Van Gellekom M.P. How low is the alpha/beta ratio for prostate cancer?. Int J Radiat Oncol Biol Phys 57 (2003) 1116-1121
20. Wang J.Z., Li X.A., Yu C.X., et al. The low alpha/beta ratio for prostate cancer: What does the clinical outcome of HDR brachytherapy tell us?. Int J Radiat Oncol Biol Phys 57 (2003) 1101-1108
21. Stone N.N., Potters L., Davis B.J., et al. Customized dose prescription for permanent prostate brachytherapy: Insights from a multicenter analysis of dosimetry outcomes. Int J Radiat Oncol Biol Phys 69 (2007) 1472-1477
22. Stone NN, LP, Davis BJ, et al. Multicenter analysis of impact of high biologically effective dose (BED) on biochemical failure (Phoenix definition) and survival outcomes in patients with Gleason score 7-10 prostate cancer treated by permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2007;69:S85-S86.
23. Merrick G.S., Galbreath R.W., Butler W.M., et al. Primary Gleason pattern does not impact survival after permanent interstitial brachytherapy for Gleason score 7 prostate cancer. Cancer 110 (2007) 289-296
24. Cha C.M., Potters L., Ashley R., et al. Isotope selection for patients undergoing prostate brachytherapy. Int J Radiat Oncol Biol Phys 45 (1999) 391-395
25. Ling C.C. Permanent implants using Au-198, Pd-103 and I-125: Radiobiological considerations based on the linear quadratic model. Int J Radiat Oncol Biol Phys 23 (1992) 81-87
26. Herstein A., Wallner K., Merrick G., et al. I-125 versus Pd-103 for low-risk prostate cancer: Long-term morbidity outcomes from a prospective randomized multicenter controlled trial. Cancer J 11 (2005) 385-389